|
1
|
Colebatch AJ and Scolyer RA: Trajectories
of premalignancy during the journey from melanocyte to melanoma.
Pathology. 50:16–23. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Slominski A, Tobin DJ, Shibahara S and
Wortsman J: Melanin pigmentation in mammalian skin and its hormonal
regulation. Physiol Rev. 84:1155–1228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slominski A, Zmijewski MA and Pawelek J:
L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators
of melanocyte functions. Pigment Cell Melanoma Res. 25:14–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slominski A, Kim TK, Brozyna AA,
Janjetovic Z, Brooks DL, Schwab LP, Skobowiat C, Jóźwicki W and
Seagroves TN: The role of melanogenesis in regulation of melanoma
behavior: Melanogenesis leads to stimulation of HIF-1α expression
and HIF-dependent attendant pathways. Arch Biochem Biophys.
563:79–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slominski RM, Zmijewski MA and Slominski
AT: The role of melanin pigment in melanoma. Exp Dermatol.
24:258–259. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hyams DM, Cook RW and Buzaid AC:
Identification of risk in cutaneous melanoma patients: Prognostic
and predictive markers. J Surg Oncol. 119:175–186. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ugurel S, Rohmel J, Ascierto PA, Flaherty
KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur
GA, et al: Survival of patients with advanced metastatic melanoma:
The impact of novel therapies-update 2017. Eur J Cancer.
83:247–257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Read J, Wadt KA and Hayward NK: Melanoma
genetics. J Med Genet. 53:1–14. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koelblinger P, Dornbierer J and Dummer R:
A review of binimetinib for the treatment of mutant cutaneous
melanoma. Future Oncol. 13:1755–1766. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Silva IP and Long GV: Systemic therapy in
advanced melanoma: Integrating targeted therapy and immunotherapy
into clinical practice. Curr Opin Oncol. 29:484–492. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
da Silveira Nogueira Lima JP, Georgieva M,
Haaland B and de Lima Lopes G: A systematic review and network
meta-analysis of immunotherapy and targeted therapy for advanced
melanoma. Cancer Med. 6:1143–1153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Appenzeller S, Gesierich A, Thiem A,
Hufnagel A, Jessen C, Kneitz H, Regensburger M, Schmidt C,
Zirkenbach V, Bischler T, et al: The identification of
patient-specific mutations reveals dual pathway activation in most
patients with melanoma and activated receptor tyrosine kinases in
BRAF/NRAS wild-type melanomas. Cancer. 125:586–600. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Winder M and Virós A: Mechanisms of drug
resistance in melanoma. Handb Exp Pharmacol. 249:91–108. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slominski AT and Carlson JA: Melanoma
resistance: A bright future for academicians and a challenge for
patient advocates. Mayo Clin Proc. 89:429–433. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cirenajwis H, Ekedahl H, Lauss M, Harbst
K, Carneiro A, Enoksson J, Rosengren F, Werner-Hartman L, Törngren
T, Kvist A, et al: Molecular stratification of metastatic melanoma
using gene expression profiling: Prediction of survival outcome and
benefit from molecular targeted therapy. Oncotarget. 6:12297–12309.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang J, Kong D, Cui Q, Wang K, Zhang D,
Gong Y and Wu G: Prognostic genes of breast cancer identified by
gene Co-expression network analysis. Front Oncol. 8:3742018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rahmani B, Zimmermann MT, Grill DE,
Kennedy RB, Oberg AL, White BC, Poland GA and McKinney BA:
Recursive indirect-paths modularity (RIP-M) for detecting community
structure in RNA-Seq Co-expression networks. Front Genet. 7:802016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gene Ontology Consortium: Gene ontology
consortium: Going forward. Nucleic Acids Res 43 (Database Issue).
D1049–D1056. 2015. View Article : Google Scholar
|
|
19
|
Kanehisa M, Sato Y, Kawashima M, Furumichi
M and Tanabe M: KEGG as a reference resource for gene and protein
annotation. Nucleic Acids Res. 44:D457–D462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su G, Morris JH, Demchak B and Bader GD:
Biological network exploration with Cytoscape 3. Curr Protoc
Bioinformatics. 47:8.13.1–24. 2014. View Article : Google Scholar
|
|
21
|
Cheng F, Desai RJ, Handy DE, Wang R,
Schneeweiss S, Barabási AL and Loscalzo J: Network-based approach
to prediction and population-based validation of in silico drug
repurposing. Nat Commun. 9:26912018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rajabi P, Bagheri M and Hani M: Expression
of estrogen receptor alpha in malignant melanoma. Adv Biomed Res.
6:142017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Testori A, Ribero S and Bataille V:
Diagnosis and treatment of in-transit melanoma metastases. Eur J
Surg Oncol. 43:544–560. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Balkwill F: Cancer and the chemokine
network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nazari A, Khorramdelazad H and Hassanshahi
G: Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes
in the pathogenesis of bladder cancer. Int J Clin Oncol.
22:991–1000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishikawa T, Nakashiro K, Hara S, Klosek
SK, Li C, Shintani S and Hamakawa H: CXCR4 expression is associated
with lymph-node metastasis of oral squamous cell carcinoma. Int J
Oncol. 28:61–66. 2006.PubMed/NCBI
|
|
27
|
Wu J, Wu X, Liang W, Chen C, Zheng L and
An H: Clinicopathological and prognostic significance of chemokine
receptor CXCR4 overexpression in patients with esophageal cancer: A
meta-analysis. Tumour Biol. 35:3709–3715. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kodama J, Hasengaowa, Kusumoto T, Seki N,
Matsuo T, Ojima Y, Nakamura K, Hongo A and Hiramatsu Y: Association
of CXCR4 and CCR7 chemokine receptor expression and lymph node
metastasis in human cervical cancer. Ann Oncol. 18:70–76. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Konoplev S, Rassidakis GZ, Estey E,
Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M
and Medeiros LJ: Overexpression of CXCR4 predicts adverse overall
and event-free survival in patients with unmutated FLT3 acute
myeloid leukemia with normal karyotype. Cancer. 109:1152–1156.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mitchell B, Leone D, Feller K, Menon S,
Bondzie P, Yang S, Park HY and Mahalingam M: Protein expression of
the chemokine receptor CXCR4 and its ligand CXCL12 in primary
cutaneous melanoma-biomarkers of potential utility? Hum Pathol.
45:2094–2100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leung GA, Cool T, Valencia CH, Worthington
A, Beaudin AE and Forsberg EC: The lymphoid-associated interleukin
7 receptor (IL7R) regulates tissue-resident macrophage development.
Development. 146(pii): dev1761802019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vitiello G, Losi GR, Amarante MK,
Ceribelli JR, Carmelo E and Watanabe M: Interleukin 7 receptor
alpha Thr244Ile genetic polymorphism is associated with
susceptibility and prognostic markers in breast cancer subgroups.
Cytokine. 103:121–126. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim MJ, Choi SK, Hong SH, Eun JW, Nam SW,
Han JW and You JS: Oncogenic IL7R is downregulated by histone
deacetylase inhibitor in esophageal squamous cell carcinoma via
modulation of acetylated FOXO1. Int J Oncol. 53:395–403.
2018.PubMed/NCBI
|
|
35
|
Oliveira DM, Santamaria G, Laudanna C,
Migliozzi S, Zoppoli P, Quist M, Grasso C, Mignogna C, Elia L,
Faniello MC, et al: Identification of copy number alterations in
colon cancer from analysis of amplicon-based next generation
sequencing data. Oncotarget. 9:20409–20425. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pridham KJ, Varghese RT and Sheng Z: The
role of Class IA phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunits in glioblastoma. Front Oncol. 7:3122017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Semba S, Itoh N, Ito M, Youssef EM, Harada
M, Moriya T, Kimura W and Yamakawa M: Down-regulation of PIK3CG, a
catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG
hypermethylation in human colorectal carcinoma. Clin Cancer Res.
8:3824–3831. 2002.PubMed/NCBI
|
|
40
|
Gorlov I, Orlow I, Ringelberg C, Hernando
E, Ernstoff MS, Cheng C, Her S, Parker JS, Thompson CL,
Gerstenblith MR, et al: Identification of gene expression levels in
primary melanoma associated with clinically meaningful
characteristics. Melanoma Res. 28:380–389. 2018.PubMed/NCBI
|
|
41
|
Abou DI, Jabbour E, Short NJ and Ravandi
F: Treatment of philadelphia chromosome-positive acute
lymphoblastic leukemia. Curr Treat Options Oncol. 20:42019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao Y and Adjei AA: Targeting
angiogenesis in cancer therapy: Moving beyond vascular endothelial
growth factor. Oncologist. 20:660–673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Deeks ED: Ibrutinib: A review in chronic
lymphocytic leukaemia. Drugs. 77:225–236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shaguft a and Ahmad I: Tamoxifen a
pioneering drug: An update on the therapeutic potential of
tamoxifen derivatives. Eur J Med Chem. 143:515–531. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guerrero-Garcia TA, Mogollon RJ and
Castillo JJ: Bortezomib in plasmablastic lymphoma: A glimpse of
hope for a hard-to-treat disease. Leuk Res. 62:12–16. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rai R, Shenoy MM, Viswanath V, Sarma N,
Majid I and Dogra S: Contact sensitivity in patients with venous
leg ulcer: A multi-centric Indian study. Int Wound J. 15:618–622.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vemuri P, Harris KE, Suh LA and Grammer
LC: Preparation of benzylpenicilloyl-polylysine: A preliminary
study. Allergy Asthma Proc. 25:165–168. 2004.PubMed/NCBI
|
|
48
|
Yazdanyar S, Zarchi K and Jemec GBE: Pain
during topical photodynamic therapy-comparing methyl
aminolevulinate (Metvix®) to aminolaevulinic acid
(Ameluz®); an intra-individual clinical study.
Photodiagnosis Photodyn Ther. 20:6–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jour G, Ivan D and Aung PP: Angiogenesis
in melanoma: An update with a focus on current targeted therapies.
J Clin Pathol. 69:472–483. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ribatti D: Tumor refractoriness to
anti-VEGF therapy. Oncotarget. 7:46668–46677. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ott PA, Hodi FS and Buchbinder EI:
Inhibition of immune checkpoints and vascular endothelial growth
factor as combination therapy for metastatic melanoma: An overview
of rationale, preclinical evidence, and initial clinical data.
Front Oncol. 5:2022015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Decoster L, Vande BI, Neyns B, Majois F,
Baurain JF, Rottey S, Rorive A, Anckaert E, De Mey J, De Brakeleer
S and De Grève J: Biomarker analysis in a Phase II study of
sunitinib in patients with advanced melanoma. Anticancer Res.
35:6893–6899. 2015.PubMed/NCBI
|
|
53
|
Urbonas V, Schadendorf D, Zimmer L, Danson
S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C,
et al: Paclitaxel with or without trametinib or pazopanib in
advanced wild-type BRAF melanoma (PACMEL): A multicentre,
open-label, randomised, controlled phase II trial. Ann Oncol.
30:317–324. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fruehauf JP, El-Masry M, Osann K,
Parmakhtiar B, Yamamoto M and Jakowatz JG: Phase II study of
pazopanib in combination with paclitaxel in patients with
metastatic melanoma. Cancer Chemother Pharmacol. 82:353–360. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hong DS, Kurzrock R, Falchook GS, Andresen
C, Kwak J, Ren M, Xu L, George GC, Kim KB, Nguyen LM, et al: Phase
1b study of lenvatinib (E7080) in combination with temozolomide for
treatment of advanced melanoma. Oncotarget. 6:43127–43134. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Noguchi S, Shibutani S, Fukushima K, Mori
T, Igase M and Mizuno T: Bosutinib, an SRC inhibitor, induces
caspase-independent cell death associated with permeabilization of
lysosomal membranes in melanoma cells. Vet Comp Oncol. 16:69–76.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Skoko J, Rožanc J, Charles EM, Alexopoulos
LG and Rehm M: Post-treatment de-phosphorylation of p53 correlates
with dasatinib responsiveness in malignant melanoma. BMC Cell Biol.
19:282018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Archibald WJ, Meacham PJ, Williams AM,
Baran AM, Victor AI, Barr PM, Sahasrahbudhe DM and Zent CS:
Management of melanoma in patients with chronic lymphocytic
leukemia. Leuk Res. 71:43–46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Eisen T, Marais R, Affolter A, Lorigan P,
Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD,
et al: Sorafenib and dacarbazine as first-line therapy for advanced
melanoma: Phase I and open-label phase II studies. Br J Cancer.
105:353–359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rossi UA, Finocchiaro L and Glikin GC:
Bortezomib enhances the antitumor effects of interferon-β gene
transfer on melanoma cells. Anticancer Agents Med Chem. 17:754–761.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ribeiro MP, Santos AE and Custódio JB:
Rethinking tamoxifen in the management of melanoma: New answers for
an old question. Eur J Pharmacol. 764:372–378. 2015. View Article : Google Scholar : PubMed/NCBI
|
